These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7596480)

  • 1. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P; Stelmasiak Z
    Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine for multiple sclerosis: review and current status.
    Sipe JC
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of cladribine treatment on beta-2 microglobin in the cerebrospinal fluid and serum of patients with multiple sclerosis].
    Niezgoda A; Losy J
    Neurol Neurochir Pol; 2000; 34(2):281-7. PubMed ID: 10962721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine. Ortho Biotech Inc.
    Tortorella C; Rovaris M; Filippi M
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.
    Niezgoda A; Losy J; Mehta PD
    Folia Morphol (Warsz); 2001 Aug; 60(3):225-8. PubMed ID: 11552664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine (2-chloro-2'-deoxyadenosine): new perspectives in clinical immunosuppression.
    Górski A; Grieb P
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):11-2. PubMed ID: 7503626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K; Wajgt A; Kondera-Anasz Z
    Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
    Laugel B; Borlat F; Galibert L; Vicari A; Weissert R; Chvatchko Y; Bruniquel D
    J Neuroimmunol; 2011 Dec; 240-241():52-7. PubMed ID: 22035961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine: limited evaluation in multiple sclerosis.
    Prescrire Int; 2011; 20(118):175. PubMed ID: 21751748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.